Clinical Trial Results
BOTOX Cosmetic shows promise for neck and lower face rejuvenation in phase 3 trial
Allergan Aesthetics, a subsidiary of AbbVie, has unveiled positive top-line findings from the second out of three Phase 3 clinical ...
Anthos’ ABP-959 outperforms Xarelto in preventing bleeding events in phase 2 trial
Blackstone Life Sciences’ substantial $250 million investment in an ex-Novartis drug candidate has yielded yet another positive outcome in its ...
ILiAD’s nasal vaccine prevents whooping cough infection in phase 2b trial
ILiAD Biotechnologies, a Florida-based biotech company, is celebrating a significant milestone in the development of its whooping cough vaccine. In ...
J&J’s Rybrevant Beats Chemo In Lung Cancer Patients Who Failed Tagrisso
The medical community buzzed with anticipation when Johnson & Johnson (J&J) released information about Rybrevant, their latest drug venture into ...
Janssen Drops Cidara’s Flu Medicine After Disappointing Phase 2 Results
Janssen is honoring its 2021 agreement with Cidara Therapeutics regarding the development of CD388, a flu prophylaxis treatment. However, Janssen ...
Bavarian Nordic Abandons COVID Booster After Failing to Protect Against New Variants
Bavarian Nordic, a Danish biotech firm, has faced a crossroads that shines a light on the ever-evolving nature of the ...
Roche’s Alecensa beats chemo in early-stage lung cancer, following Tecentriq’s lead
With Tecentriq approval, Roche is once again celebrating success, this time in a promising early-stage lung cancer trial starring Alecensa, ...
Mezigdomide, a new oral drug for multiple myeloma, shows ‘modest’ survival benefit in phase 1 trial
A new oral drug for multiple myeloma, mezigdomide, has shown a ‘modest’ survival benefit in a phase 1 trial involving ...
Navigating Peaks and Valleys: Novocure’s Tumor Treating Fields Unveil Divergent Outcomes
In the complex realm of medical breakthroughs, the journey from triumph to setback can be as unpredictable as it is ...
BridgeBio Exposes Phase 3 Acoramidis Insights, Mortality Figures
In the intricate dance of scientific exploration, BridgeBio has taken a resolute plunge into the depths of phase 3 acoramidis ...
Bayer Advances Parkinson’s Cell Therapy to Phase 2 Trial
A new horizon gleams for Bayer’s quest to conquer Parkinson’s disease through advanced cell therapy. In a significant revelation, the ...
Exelixis Celebrates Early End to Cabometyx Trial for Neuroendocrine Tumors due to Remarkable Efficacy
Exelixis, a drug developer, recently halted a cancer trial involving Cabometyx, their tyrosine kinase inhibitor, due to an overwhelming display ...
Roche Unveils Interim TIGIT Overall Survival Data Following Unintended Release, Triggering Surge in Stocks
An unexpected revelation has provided the world with a sneak peek into Roche’s highly anticipated TIGIT data. Roche, which had ...
How Remibrutinib, a Novartis Drug, Can Heal Your Hives
Source – Novartis Novartis has unveiled promising initial outcomes from the Phase III REMIX-1 and REMIX-2 trials assessing the effectiveness ...
Apogee Doses First Patients in Phase I Trial of APG777
Source – Apogee Therapeutics Apogee Therapeutics has embarked on a significant milestone by commencing the dosing of healthy volunteers in ...
PFS in Patients with Platinum-Resistant Ovarian Cancer Is Not Improved by Batiraxcept
Source – Aravive The Phase III AXLerate-OC trial (NCT04300140) assessing the combination of batiraxcept with paclitaxel has not met its ...
Bavarian Nordic’s Chikungunya Vaccine Shines in Phase III Trials, Poses Strong Challenge to Valneva’s Dominance
Source – Bavarian Nordic Bavarian Nordic has achieved a significant milestone with its chikungunya virus vaccine candidate, marking its second ...
Eli Lilly’s Tirzepatide Succeeds in 2 More Late-Stage Obesity Trials Ahead of FDA Decision
Source – Eli Lilly Eli Lilly continues to gather strong evidence supporting the effectiveness of tirzepatide, its dual GIP/GLP-1 agonist, ...
Merck’s V116 Vaccine Shows Positive Results in Phase III Trials
Source – Merck Merck, known as MSD outside of the United States and Canada, has announced highly encouraging initial results ...
Merck and Moderna Commence Phase III Study of V940 with KEYTRUDA for High-Risk Melanoma
Source – Merck Moderna and Merck announced the commencement of the pivotal Phase III randomized V940-001 clinical trial. This trial ...
Continue to Evaluate TTFields in Pancreatic Cancer in the PANOVA-3 Trial
Source – Novocure The Phase III PANOVA-3 trial, which is assessing Tumor Treating Fields (TTFields) therapy in combination with nab-paclitaxel ...
Twice-Yearly Lenacapavir Boosts HIV Patients’ Quality of Life
Source – Gilead Gilead Sciences presented new data at the 12th International AIDS Society (IAS) Conference on HIV Science (IAS ...
Discontinuation of LOTIS-9 Trial: Zynlonta in Unfit DLBCL Patients
Source – ADC Therapeutics On July 20, 2023, ADC Therapeutics announced its decision to discontinue the Phase II LOTIS-9 clinical ...
KEYNOTE-A18 Trial: Primary Endpoint – Progression-Free Survival in High-Risk Cervical Cancer
Source – Merck Merck has announced a groundbreaking development in its Phase III KEYNOTE-A18 trial, also referred to as ENGOT-cx11/GOG-3047. ...
Some individuals’ cognitive deterioration may be slowed by hearing aids
Amid the focus on expensive therapies targeting amyloid for Alzheimer’s disease, a new clinical study highlights an alternative approach to ...
Lazertinib Beats Gefitinib in Treating EGFR-Mutated NSCLC
In a Phase III study known as LASER301 (NCT04248829) and published in the Journal of Clinical Oncology, lazertinib (formerly YH25448), ...
BridgeBio Reports Improved Data for ATTR Cardiomyopathy Drug
Source – BridgeBio BridgeBio is preparing to seek FDA approval for its acoramidis drug to treat transthyretin amyloidosis (ATTR) cardiomyopathy, ...
Treatment for Advanced HNSCC With ASP-1929 and Anti-EGFR Therapy Is Effective
Source – Rakuten Medical Promising early results have been observed with ASP-1929, in combination with anti-PD-1 therapy, for patients with ...
First Wave BioPharma’s Pancreatic Enzyme Replacement Therapy Faces Hurdles, Stock Plummets
Source – First Wave BioPharma First Wave BioPharma, formerly known as AzurRx BioPharma, has faced ongoing challenges in bringing a ...
Promising Phase III Results: OCREVUS (Ocrelizumab) Subcutaneous Injection Offers Convenient and Efficient Treatment for Multiple Sclerosis
Source – Roche On 13 July Roche announced positive results from the Phase III OCARINA II trial, which investigated the ...
